Tag: Med Alliance
Med Alliance raises US$37 million to launch sirolimus drug-coated balloon
Med Alliance SA, a company developing and commercialising the first sirolimus micro-reservoir drug-coated balloon (SELUTION DCB) to treat patients suffering from peripheral artery disease...
First-in-man SELUTION study achieves primary endpoint
Primary endpoint data from the first-in-man study of SELUTION, Med Alliance’s novel sirolimus-coated balloon, were presented at the Leipzig Interventional Course (LINC; 29 January–2...
First-in-man study of Med Alliance’s Selution sirolimus-coated balloon completes enrolment
Med Alliance has announced the on-schedule completion of patient enrolment in the first-in-man (FIM) study of Selution, the company’s sirolimus-coated balloon. Fifty patients have...
Initial patients enrolled in first-in-man study of Selution sirolimus-coated balloon
Med Alliance has announced first patient enrolment in the first-in-man study of the Selution novel sirolimus-coated balloon. Patients were enrolled at the Universitaets-Herzzentrum, Bad...
